StockUS listing USACADNASDAQHealthcareQuality Compounder

ACADIA Pharmaceuticals Inc(ACAD) Stock Analysis | Healthcare

USD --+0.00%
Reward69High
Risk29Low
75%Data
Strong 30% profit margin · Revenue growing 23% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 2.96Bn
Reward Ratingⓘ69 High reward assessment · 75% data coverage
Top 25% of stocksView factors
Risk Ratingⓘ29 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ACAD to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is ACADIA Pharmaceuticals Inc?

, a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

AI Brief Pro

The brief on ACADIA Pharmaceuticals Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is ACADIA Pharmaceuticals Inc?

, a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 2.96B, and a P/E ratio of 8.3x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: High (69)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
P/E Ratio8.3058
Beta0.885
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
13,321 shares
$69k
0
3-6months
753,521 shares
$1.4M
0
6-9months
1225,183 shares
$546k
0
9-12months
0
0